Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Veeva SystemsVEEV +5.82%88 Debt-to-Equity is 0.01 as of Apr. 2026, which is 50% below its 10-year median of 0.02. GuruFocus rates VEEV with a GF Score™ of 88/100 and a GF Value™ of $290.40 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 556 Healthcare Providers & Services companies, Veeva Systems ranks better than 99.82% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Veeva Systems's Debt-to-Equity or its related term are showing as below:
VEEV'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.01 Med: 0.02 Max: 0.03
Current: 0.01
During the past 13 years, the highest Debt-to-Equity Ratio of Veeva Systems was 0.03. The lowest was 0.01. And the median was 0.02.
VEEV's Debt-to-Equity is ranked better than 99.82% of 556
companies
in the Healthcare Providers & Services industry
Industry Median: 0.42
vs VEEV: 0.01
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Veeva Systems Debt-to-Equity Related Terms
Veeva Systems Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Veeva Systems's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Health Information Services subindustry, Veeva Systems's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Veeva Systems Debt-to-Equity vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Veeva Systems's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Veeva Systems's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Veeva Systems (VEEV) has a Debt-to-Equity of 0.01 as of Apr. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Veeva Systems and its competitors. This is 50% below median its historical median of 0.02. Over the past decade, Veeva Systems' Debt-to-Equity has ranged from 0.01 to 0.03. According to the industry distribution chart, Veeva Systems ranks #1 out of 556 companies in the Healthcare Providers & Services industry, placing it in the top 0.2%.
Is Veeva Systems' Debt-to-Equity too high?
Veeva Systems' current Debt-to-Equity of 0.01 is 50% below median its 10-year median of 0.02. Over the past 10 years, this metric has ranged from a low of 0.01 to a high of 0.03. The Healthcare Providers & Services industry median Debt-to-Equity is 0.42. Veeva Systems' value of 0.01 is 97.6% below this industry median. Based on the distribution chart, Veeva Systems ranks #1 out of 556 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Veeva Systems has a GF Score™ of 88/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Veeva Systems' Debt-to-Equity compare to BTSG and HQY?
According to the Healthcare Providers & Services industry distribution chart, Veeva Systems ranks #1 out of 556 companies for Debt-to-Equity. This places Veeva Systems in the top 0% of its industry — outperforming the majority of peers. The industry median Debt-to-Equity is 0.42. Veeva Systems' value of 0.01 is 97.6% below this benchmark. Historically, Veeva Systems' own Debt-to-Equity has ranged from 0.01 to 0.03 over the past decade. While the company's 10-year median is 0.02 vs. the industry median of 0.42, Veeva Systems has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Healthcare Providers & Services company?
The median Debt-to-Equity among Healthcare Providers & Services companies is 0.42, based on 556 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Veeva Systems's current Debt-to-Equity of 0.01 is 97.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Veeva Systems and its competitors. For the Healthcare Providers & Services industry, the median Debt-to-Equity is 0.42 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Veeva Systems's current Debt-to-Equity is 0.01, which is 50% below median its own 10-year median of 0.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Veeva Systems stock overvalued right now?
Based on GuruFocus' analysis, Veeva Systems (VEEV) is currently considered Modestly Undervalued. The stock's GF Value™ is $290.40, compared to a current price of $230.47 — trading 20.6% below its estimated fair value. The current Debt-to-Equity is 0.01, which is 50% below median its 10-year median of 0.02 and 97.6% below the Healthcare Providers & Services industry median of 0.42. Veeva Systems' overall GF Score™ is 88/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Veeva Systems (VEEV), the current Debt-to-Equity is 0.01 as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Veeva Systems (VEEV) Overvalued in 2026?
Based on GuruFocus' analysis, Veeva Systems stock appears to be undervalued.
The current stock price of $230.47 is trading 20.6% below its estimated GF Value™ of $290.40.
GuruFocus considers Veeva Systems to be Modestly Undervalued.
Key valuation signals for VEEV:
Debt-to-Equity: 0.01 (50% below median its 10-year median of 0.02)
GF Value™: $290.40 vs. price of $230.47 (20.6% below fair value)
Industry Position: 97.6% below the Healthcare Providers & Services median (#1 of 556)
No single metric tells the full story. See the VEEV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Veeva is the global leading supplier of cloud-based software solutions for the life sciences industry. The company's best-of-breed offerings address operating and regulatory requirements for customers ranging from small, emerging biotechnology companies to departments of global pharmaceutical manufacturers. The company leverages its domain expertise to improve the efficiency and compliance of the underserved life sciences industry, displacing large, highly customized and dated enterprise resource planning systems that have limited flexibility. Its two main products are Veeva CRM, a customer relationship management platform for companies with a salesforce, and Veeva Vault, a content management platform that tackles various functions within any life sciences company.
88GF Score
Get the complete analysis for VEEV
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VEEV has been successfully added to your 
